{"pmid":32374416,"title":"ACE2 and prognosis of COVID-19. Insights from Bartter's and Gitelman's syndromes patients.","text":["ACE2 and prognosis of COVID-19. Insights from Bartter's and Gitelman's syndromes patients.","The relationship between Renin-Angiotensin system (RAS) and COVID-19 pandemic and, in particular, RAS as part of the CoV-2 infection process via Angiotensin Converting Enzyme 2 (ACE2), the entry point of SARS-CoV-2, has resulted in conflicting suggestions regarding how RAS and its role(s) should inform treating COVID-19. ACE inhibitors or angiotensin II (Ang)-type 1 receptor blockers (ARBs), in fact, have been suggested to be avoided as they potentially upregulate ACE2 (1) and, conversely, there are suggestions that ARBs might be beneficial (2) as SARS-CoV-2 causing ACE2 downregulation slows the Ang II conversion to the vasodilatory, anti-inflammatory, antioxidant and antiatherosclerotic Ang 1-7 (3-5) , and the use of ARBs by blocking the excessive Ang II type-1 receptors activation, would be beneficial upregulating ACE2 activity and increasing Ang 1-7 levels. This article is protected by copyright. All rights reserved.","J Med Virol","Calo, Lorenzo A","Davis, Paul A","Rigato, Matteo","Sgarabotto, Luca","32374416"],"abstract":["The relationship between Renin-Angiotensin system (RAS) and COVID-19 pandemic and, in particular, RAS as part of the CoV-2 infection process via Angiotensin Converting Enzyme 2 (ACE2), the entry point of SARS-CoV-2, has resulted in conflicting suggestions regarding how RAS and its role(s) should inform treating COVID-19. ACE inhibitors or angiotensin II (Ang)-type 1 receptor blockers (ARBs), in fact, have been suggested to be avoided as they potentially upregulate ACE2 (1) and, conversely, there are suggestions that ARBs might be beneficial (2) as SARS-CoV-2 causing ACE2 downregulation slows the Ang II conversion to the vasodilatory, anti-inflammatory, antioxidant and antiatherosclerotic Ang 1-7 (3-5) , and the use of ARBs by blocking the excessive Ang II type-1 receptors activation, would be beneficial upregulating ACE2 activity and increasing Ang 1-7 levels. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Calo, Lorenzo A","Davis, Paul A","Rigato, Matteo","Sgarabotto, Luca"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374416","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25978","keywords":["ace2","bartter's syndrome","covid-19","gitelman's syndrome"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496354484224,"score":9.490897,"similar":[{"pmid":32340044,"title":"The ACE-2 in COVID-19: Foe or Friend?","text":["The ACE-2 in COVID-19: Foe or Friend?","COVID-19 is a rapidly spreading outbreak globally. Emerging evidence demonstrates that older individuals and people with underlying metabolic conditions of diabetes mellitus, hypertension, and hyperlipidemia are at higher risk of morbidity and mortality. The SARS-CoV-2 infects humans through the angiotensin converting enzyme (ACE-2) receptor. The ACE-2 receptor is a part of the dual system renin-angiotensin-system (RAS) consisting of ACE-Ang-II-AT1R axis and ACE-2-Ang-(1-7)-Mas axis. In metabolic disorders and with increased age, it is known that there is an upregulation of ACE-Ang-II-AT1R axis with a downregulation of ACE-2-Ang-(1-7)-Mas axis. The activated ACE-Ang-II-AT1R axis leads to pro-inflammatory and pro-fibrotic effects in respiratory system, vascular dysfunction, myocardial fibrosis, nephropathy, and insulin secretory defects with increased insulin resistance. On the other hand, the ACE-2-Ang-(1-7)-Mas axis has anti-inflammatory and antifibrotic effects on the respiratory system and anti-inflammatory, antioxidative stress, and protective effects on vascular function, protects against myocardial fibrosis, nephropathy, pancreatitis, and insulin resistance. In effect, the balance between these two axes may determine the prognosis. The already strained ACE-2-Ang-(1-7)-Mas in metabolic disorders is further stressed due to the use of the ACE-2 by the virus for entry, which affects the prognosis in terms of respiratory compromise. Further evidence needs to be gathered on whether modulation of the renin angiotensin system would be advantageous due to upregulation of Mas activation or harmful due to the concomitant ACE-2 receptor upregulation in the acute management of COVID-19.","Horm Metab Res","Dalan, Rinkoo","Bornstein, Stefan R","El-Armouche, Ali","Rodionov, Roman N","Markov, Alexander","Wielockx, Ben","Beuschlein, Felix","Boehm, Bernhard O","32340044"],"abstract":["COVID-19 is a rapidly spreading outbreak globally. Emerging evidence demonstrates that older individuals and people with underlying metabolic conditions of diabetes mellitus, hypertension, and hyperlipidemia are at higher risk of morbidity and mortality. The SARS-CoV-2 infects humans through the angiotensin converting enzyme (ACE-2) receptor. The ACE-2 receptor is a part of the dual system renin-angiotensin-system (RAS) consisting of ACE-Ang-II-AT1R axis and ACE-2-Ang-(1-7)-Mas axis. In metabolic disorders and with increased age, it is known that there is an upregulation of ACE-Ang-II-AT1R axis with a downregulation of ACE-2-Ang-(1-7)-Mas axis. The activated ACE-Ang-II-AT1R axis leads to pro-inflammatory and pro-fibrotic effects in respiratory system, vascular dysfunction, myocardial fibrosis, nephropathy, and insulin secretory defects with increased insulin resistance. On the other hand, the ACE-2-Ang-(1-7)-Mas axis has anti-inflammatory and antifibrotic effects on the respiratory system and anti-inflammatory, antioxidative stress, and protective effects on vascular function, protects against myocardial fibrosis, nephropathy, pancreatitis, and insulin resistance. In effect, the balance between these two axes may determine the prognosis. The already strained ACE-2-Ang-(1-7)-Mas in metabolic disorders is further stressed due to the use of the ACE-2 by the virus for entry, which affects the prognosis in terms of respiratory compromise. Further evidence needs to be gathered on whether modulation of the renin angiotensin system would be advantageous due to upregulation of Mas activation or harmful due to the concomitant ACE-2 receptor upregulation in the acute management of COVID-19."],"journal":"Horm Metab Res","authors":["Dalan, Rinkoo","Bornstein, Stefan R","El-Armouche, Ali","Rodionov, Roman N","Markov, Alexander","Wielockx, Ben","Beuschlein, Felix","Boehm, Bernhard O"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32340044","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1055/a-1155-0501","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494297178112,"score":533.6884},{"pmid":32369211,"title":"What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?","text":["What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?","Angiotensin-converting enzyme 2 (ACE2) removes a single residue from Ang I to yield Ang (1-9) and cleaves a single residue from Ang II to generate Ang (1-7). Thus ACE2 counterbalances ACE function decreasing Ang II levels(1) . Consequently, this enzyme has a protective role against excessively high blood pressure values and high level of renin-angiotensin system (RAS) activation(2) . This article is protected by copyright. All rights reserved.","J Med Virol","Froldi, Guglielmina","32369211"],"abstract":["Angiotensin-converting enzyme 2 (ACE2) removes a single residue from Ang I to yield Ang (1-9) and cleaves a single residue from Ang II to generate Ang (1-7). Thus ACE2 counterbalances ACE function decreasing Ang II levels(1) . Consequently, this enzyme has a protective role against excessively high blood pressure values and high level of renin-angiotensin system (RAS) activation(2) . This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Froldi, Guglielmina"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369211","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25974","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496229703680,"score":527.291},{"pmid":32333398,"title":"A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance.","text":["A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance.","Angiotensin converting enzyme-2 (ACE2) is the receptor for the coronavirus SARS-CoV-2, which causes COVID-19. We propose the following hypothesis: Imbalance in the action of ACE1- and ACE2-derived peptides, thereby enhancing Angiotensin-II (ANG II) signaling, a primary driver of COVID-19 pathobiology. ACE1/ACE2 imbalance occurs due to the binding of SARS-CoV-2 to ACE2, reducing ACE2-mediated conversion of ANG II to ANG peptides that counteract pathophysiological effects of ACE1-generated ANGII. This hypothesis suggests several approaches to treat COVID-19 by restoring ACE1/ACE2 balance: 1) ANG II receptor blockers (ARBs); 2) ACE1 inhibitors (ACEIs); 3) Agonists of receptors activated by ACE2-derived peptides [e.g., ANG (1-7), which activates MAS1]; 4) Recombinant human ACE2 or ACE2 peptides as decoys for the virus. Reducing ACE1/ACE2 imbalance is predicted to blunt COVID-19-associated morbidity and mortality, especially in vulnerable patients. Importantly, approved ARBs and ACEIs can be rapidly repurposed to test their efficacy in treating COVID-19.","Br J Pharmacol","Sriram, Krishna","Insel, Paul A","32333398"],"abstract":["Angiotensin converting enzyme-2 (ACE2) is the receptor for the coronavirus SARS-CoV-2, which causes COVID-19. We propose the following hypothesis: Imbalance in the action of ACE1- and ACE2-derived peptides, thereby enhancing Angiotensin-II (ANG II) signaling, a primary driver of COVID-19 pathobiology. ACE1/ACE2 imbalance occurs due to the binding of SARS-CoV-2 to ACE2, reducing ACE2-mediated conversion of ANG II to ANG peptides that counteract pathophysiological effects of ACE1-generated ANGII. This hypothesis suggests several approaches to treat COVID-19 by restoring ACE1/ACE2 balance: 1) ANG II receptor blockers (ARBs); 2) ACE1 inhibitors (ACEIs); 3) Agonists of receptors activated by ACE2-derived peptides [e.g., ANG (1-7), which activates MAS1]; 4) Recombinant human ACE2 or ACE2 peptides as decoys for the virus. Reducing ACE1/ACE2 imbalance is predicted to blunt COVID-19-associated morbidity and mortality, especially in vulnerable patients. Importantly, approved ARBs and ACEIs can be rapidly repurposed to test their efficacy in treating COVID-19."],"journal":"Br J Pharmacol","authors":["Sriram, Krishna","Insel, Paul A"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333398","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bph.15082","keywords":["ace inhibitor","ace2","angiotensin","angiotensin receptor blocker","covid-19","sars-cov-2"],"e_drugs":["Peptides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493953245184,"score":524.5517},{"pmid":32469114,"title":"An update on ACE2 amplification and its therapeutic potential.","text":["An update on ACE2 amplification and its therapeutic potential.","The renin angiotensin system (RAS) plays an important role in the pathogenesis of variety of diseases. Targeting the formation and action of angiotensin II (Ang II), the main RAS peptide, has been the key therapeutic target for last three decades. ACE-related carboxypeptidase (ACE2), a monocarboxypeptidase that had been discovered 20 years ago, is one of the catalytically most potent enzymes known to degrade Ang II to Ang-(1-7), a peptide that is increasingly accepted to have organ -protective properties that oppose and counterbalance those of Ang II. In addition to its role as a RAS enzyme ACE2 is the main receptor for SARS-CoV-2. In this review, we discuss various strategies that have been used to achieve amplification of ACE2 activity including the potential therapeutic potential of soluble recombinant ACE2 protein and novel shorter ACE2 variants.","Acta Physiol (Oxf)","Marquez, Alonso","Wysocki, Jan","Pandit, Jay","Batlle, Daniel","32469114"],"abstract":["The renin angiotensin system (RAS) plays an important role in the pathogenesis of variety of diseases. Targeting the formation and action of angiotensin II (Ang II), the main RAS peptide, has been the key therapeutic target for last three decades. ACE-related carboxypeptidase (ACE2), a monocarboxypeptidase that had been discovered 20 years ago, is one of the catalytically most potent enzymes known to degrade Ang II to Ang-(1-7), a peptide that is increasingly accepted to have organ -protective properties that oppose and counterbalance those of Ang II. In addition to its role as a RAS enzyme ACE2 is the main receptor for SARS-CoV-2. In this review, we discuss various strategies that have been used to achieve amplification of ACE2 activity including the potential therapeutic potential of soluble recombinant ACE2 protein and novel shorter ACE2 variants."],"journal":"Acta Physiol (Oxf)","authors":["Marquez, Alonso","Wysocki, Jan","Pandit, Jay","Batlle, Daniel"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469114","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/apha.13513","keywords":["ace2","angiotensin -(1-7)","angiotensin ii","covid 19","therapeutic"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668167110084263937,"score":513.76337},{"pmid":32492292,"title":"Two hits to the renin-angiotensin system may play a key role in severe COVID-19.","text":["Two hits to the renin-angiotensin system may play a key role in severe COVID-19.","The spike glycoprotein on the virion surface docking onto the angiotensin-converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in human cells-involves downregulation of ACE2 expression with systemic renin-angiotensin system (RAS) imbalance and promotion of multi-organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1-7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS-CoV-2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1-7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID-19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID-19 infection inactivating the ACE2/Ang (1-7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID-19 who have comorbidities and may serve as a therapeutic target for COVID-19 treatment.","Kaohsiung J Med Sci","Tseng, Yu-Hsin","Yang, Rei-Cheng","Lu, Tzong-Shi","32492292"],"abstract":["The spike glycoprotein on the virion surface docking onto the angiotensin-converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in human cells-involves downregulation of ACE2 expression with systemic renin-angiotensin system (RAS) imbalance and promotion of multi-organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1-7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS-CoV-2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1-7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID-19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID-19 infection inactivating the ACE2/Ang (1-7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID-19 who have comorbidities and may serve as a therapeutic target for COVID-19 treatment."],"journal":"Kaohsiung J Med Sci","authors":["Tseng, Yu-Hsin","Yang, Rei-Cheng","Lu, Tzong-Shi"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492292","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/kjm2.12237","keywords":["coronavirus disease 2019","renin-angiotensin system)","two hits"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892169379774464,"score":501.60135}]}